BioXcel Therapeutics News

BioXcel Therapeutics Analyst Ratings

BenzingaApr 23 06:27 ET

Buy Rating Reaffirmed for BioXcel Therapeutics Amidst Expansion Opportunities and FDA-Approved IGALMI

TipRanksApr 23 06:25 ET

Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)

TipRanksApr 16 06:31 ET

Bioxcel Therapeutics: Navigating Financial Pressures and Clinical Trials – A Hold Rating Analysis

TipRanksMar 27 03:16 ET

BioXcel Therapeutics Analyst Ratings

BenzingaMar 18 06:52 ET

Buy Rating Affirmed for BioXcel Therapeutics: FDA Pathway Clear for BXCL501 Expansion

TipRanksMar 18 06:26 ET

BioXcel Therapeutics Analyst Ratings

BenzingaMar 14 07:24 ET

BioXcel Therapeutics Analyst Ratings

BenzingaMar 13 10:32 ET

Buy Rating Affirmed for BioXcel Therapeutics Amid Label Expansion and Strong Clinical Prospects

TipRanksMar 13 06:39 ET

UBS Cuts BioXcel to Neutral; Cites Regulatory Issues, Financing

Seeking AlphaFeb 21 11:03 ET

UBS Cuts BioXcel Therapeutics Stock Target to $4 on Funding Concerns

InvestingFeb 21 08:38 ET

BioXcel Therapeutics Analyst Ratings

BenzingaFeb 21 07:38 ET

Maintaining Hold Rating on Bioxcel Therapeutics Amid Financing Positives and Extended Clinical Timelines

TipRanksFeb 13 05:23 ET

Buy Rating on BioXcel Therapeutics Backed by Patent Strength and Upcoming Clinical Milestones

TipRanksFeb 6 06:26 ET

BioXcel Therapeutics: Strong Buy Rating on Patent Protections and Strategic Advancements

TipRanksFeb 5 20:28 ET

Hold Rating on Bioxcel Therapeutics Amid Financial Uncertainty and Pending Igalmi Study Details

TipRanksDec 5, 2023 02:26 ET

Analysts Offer Insights on Healthcare Companies: Tenon Medical, Inc. (TNON), Akoya Biosciences (AKYA) and Bioxcel Therapeutics (BTAI)

TipRanksNov 16, 2023 08:00 ET

HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $11 Price Target

BenzingaNov 15, 2023 06:53 ET

BioXcel Therapeutics Analyst Ratings

BenzingaNov 15, 2023 06:52 ET

Buy Rating for Bioxcel Therapeutics Supported by Positive FDA Alignment, Upcoming Trials, and Favorable Debt Renegotiation

TipRanksNov 15, 2023 06:36 ET